Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Am J Surg. 2012 Nov;204(5):643-8. doi: 10.1016/j.amjsurg.2012.07.017. Epub 2012 Aug 24.
The US Food and Drug Administration recently approved a transcatheter aortic valve for patients for whom open heart surgery is prohibitively risky.
A multidisciplinary heart valve team partnered with administration to launch a transcatheter aortic valve replacement (TAVR) program. Clinical registries were used to show robust valve caseloads and outcomes at our Veterans Affairs (VA) facility and to project future volumes. A TAVR business plan was approved by the VA leadership as part of a multiphase project to upgrade and expand our surgical facilities.
The heart valve team completed a training program that included simulations and visits to established TAVR centers. Patients were evaluated and screened through a streamlined process, and the program was initiated successfully.
Establishing a TAVR program at a VA facility requires a multidisciplinary team with experience in heart valve and endovascular therapies and a supportive administration willing to invest in a sophisticated infrastructure.
美国食品和药物管理局最近批准了一种经导管主动脉瓣，用于那些心脏直视手术风险极高的患者。
一个多学科的心脏瓣膜团队与管理部门合作，开展了经导管主动脉瓣置换术（TAVR）项目。临床注册中心显示，我们退伍军人事务部（VA）的瓣膜病例数量和结果非常可观，并预测了未来的数量。TAVR 业务计划得到了 VA 领导层的批准，作为升级和扩大我们手术设施的多阶段项目的一部分。
心脏瓣膜团队完成了一项培训计划，其中包括模拟和参观已建立的 TAVR 中心。患者通过简化的流程进行评估和筛选，该项目成功启动。
在退伍军人事务部设施中建立 TAVR 项目需要一个多学科团队，该团队具有心脏瓣膜和血管内治疗方面的经验，以及一个愿意投资于复杂基础设施的支持性管理部门。
